Journal
ONCOTARGET
Volume 8, Issue 61, Pages 104664-104686Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.22272
Keywords
T-cell prolymphocytic leukemia; morphology; cytogenetic; molecular biology; treatment
Categories
Ask authors/readers for more resources
T-prolymphocytic leukemia (T-PLL) is a rare T-cell neoplasm with an aggressive clinical course. Leukemic T-cells exhibit a post-thymic T-cell phenotype (Tdt(-), CD1a(-), CD5(+), CD2(+) and CD7(+)) and are generally CD4(+)/CD8(-), but CD4(+)/CD8(+) or CD8(+)/CD4(-) T-PLL have also been reported. The hallmark of T-PLL is the rearrangement of chromosome 14 involving genes for the subunits of the T-cell receptor (TCR) complex, leading to overexpression of the proto-oncogene TCL1. In addition, molecular analysis shows that T-PLL exhibits substantial mutational activation of the IL2RG-JAK1-JAK3-, STAT5B axis. T-PLL patients have a poor prognosis, due to a poor response to conventional chemotherapy. Monoclonal antibody therapy with antiCD52-alemtuzumab has considerably improved outcomes, but the responses to treatment are transient; hence, patients who achieve a response to therapy are considered for stem cell transplantation (SCT). This combined approach has extended the median survival to four years or more. Nevertheless, new approaches using well-tolerated therapies that target growth and survival signals are needed for most patients unable to receive intensive chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available